Results 31 to 40 of about 25,067 (205)

Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress

Biomolecules, 2022
Prior studies demonstrate the activation of poly-(ADP-ribose) polymerase 1 (PARP1) in various pathophysiological conditions, including sepsis. We have assessed the effect of olaparib, a clinically used PARP1 inhibitor, on the responses of human ...
Sidneia Sousa Santos, Milena Karina Coló Brunialti, Larissa de Oliveira Cavalcanti Peres Rodrigues, Ana Maria Alvim Liberatore, Ivan Hong Jun Koh, Vanessa Martins, Francisco Garcia Soriano, Csaba Szabo, Reinaldo Salomão   +8 more
doaj   +1 more source

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model [PDF]

, 2017
Clinical trials are studying the benefits of combining the PARP-1 inhibitor olaparib with chemotherapy and radiotherapy treatment in a variety of cancer increasing the therapeutic ratio for olaparib may come from its ability to modify the tumour ...
Mark J. O’Connor, Zafarana, Gaetano, Marcel Verheij, Rottenberg, Sven, Borst, Gerben R; id_orcid, McKee, Trevor, Bristow, Robert G; id_orcid, Ramya Kumareswaran, Seyda Telli, Bristow, Robert G, Yücel, Hatice, Trevor McKee, Borst, Gerben R, O'Connor, Mark J, Gerben R. Borst, Jos Jonkers, Kumareswaran, Ramya, Robert G. Bristow, Hatice Yücel, Trevor Do, Do, Trevor, Sven Rottenberg, Telli, Seyda, Jonkers, Jos, Verheij, Marcel, Gaetano Zafarana   +25 more
core   +1 more source

Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma

EJNMMI Research, 2022
Purpose Radiopharmaceuticals targeting poly(ADP-ribose) polymerase (PARP) have emerged as promising agents for cancer diagnosis and therapy. PARP enzymes are expressed in both cancerous and normal tissue.
Chung Ying Chan, Samantha L. Hopkins, Florian Guibbal, Anna Pacelli, Julia Baguña Torres, Michael Mosley, Doreen Lau, Patrick Isenegger, Zijun Chen, Thomas C. Wilson, Gemma Dias, Rebekka Hueting, Véronique Gouverneur, Bart Cornelissen   +13 more
doaj   +1 more source

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC

Journal of Hematology & Oncology, 2020
Background PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably used in assessment of Olaparib ...
Chenggong Sun, Wenyu Cao, Chunping Qiu, Chengcheng Li, Samina Dongol, Zhiwei Zhang, Ruifen Dong, Kun Song, Xingsheng Yang, Qing Zhang, Beihua Kong   +10 more
doaj   +1 more source

Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature

BMC Pulmonary Medicine, 2023
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has demonstrated effectiveness in treating ovarian, breast, and other cancers, particularly those with specific molecular subtypes including, but not limited to, BRCA1/2 mutations ...
Hiroshi Ishimoto, Noriho Sakamoto, Takashi Kido, Mutsumi Ozasa, Shin Tsutsui, Mayako Mori, Daichi Setoguchi, Shinnosuke Takemoto, Yasushi Obase, Yuji Ishimatsu, Chiharu Tomonaga, Kanako Matsumoto, Sachiko Morisaki, Kiyonori Miura, Hiroshi Mukae   +14 more
doaj   +1 more source

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

OncoImmunology, 2022
PARP inhibitors are synthetically lethal with BRCA1/2 mutations, and in this setting, accumulation of DNA damage leads to cell death. Because increased DNA damage and subsequent immune activation can prime an anti-tumor immune response, we studied the ...
Anna D. Staniszewska, Joshua Armenia, Matthew King, Chrysiis Michaloglou, Avinash Reddy, Maneesh Singh, Maryann San Martin, Laura Prickett, Zena Wilson, Theresa Proia, Deanna Russell, Morgan Thomas, Oona Delpuech, Mark J. O’Connor, Elisabetta Leo, Helen Angell, Viia Valge-Archer   +16 more
doaj   +1 more source

Palladacarboxamide Capping Reagents for Carbon Isotope Labeling and Pharmaceutical Diversification

Angewandte Chemie, EarlyView.
Herein, we present a method for carbon isotope labeling of arylamides via the coupling of air‐stable palladium carboxamide complexes and boronic ester/acids. A wide variety of functionalized boronic esters and acids have been coupled with simple palladium carboxamides complexes.
Daniel V. Hoffmann, Anika Schick, Lasse Kjær, Vitus J. Enemærke, Clemens Kaussler, Jens Torp, Pablo Martínez‐Pardo, Charles S. Elmore, Troels Skrydstrup   +8 more
wiley   +2 more sources

Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice

Journal of Biomedical Science, 2022
Background Seaweed polysaccharides have been recommended as anticancer supplements and for boosting human health; however, their benefits in the treatment of triple-negative breast cancers (TNBCs) and improving immune surveillance remain unclear ...
Li-Mei Chen, Pao-Pao Yang, Aushia Tanzih Al Haq, Pai-An Hwang, You-Chen Lai, Yueh-Shan Weng, Michelle Audrey Chen, Hsin-Ling Hsu   +7 more
doaj   +1 more source

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gábor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy

Translational Oncology, 2021
P-glycoprotein (P-gp) is an adenosine triphosphate (ATP)-dependent drug efflux protein commonly associated with multidrug resistance in cancer chemotherapy.
Yan Baglo, Aaron J. Sorrin, Xiaocong Pu, Cindy Liu, Jocelyn Reader, Dana M. Roque, Huang-Chiao Huang   +6 more
doaj   +1 more source